2,3-O-isopropylidene-D-ribose

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3-O-isopropylidene-D-ribose
• 英文别名: 2,3-O-isopropylidene-L-lyxofuranose；2,3-O-isopropylidene-L-lyxose；2,3-isopropylidene-L-lyxofuranose；(3aR,6S,6aR)-6-(hydroxymethyl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-ol
• 化学式: C₈H₁₄O₅
• 分子量: 190.196
• InChiKey: OYYTWUSIDMJZCP-CUWOBHIPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  68.2
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2,3-O-isopropylidene-D-ribose 在 水 作用下， 以95%的产率得到L-来苏糖
  参考文献：
  名称：

  从天然存在的d糖中 合成l lyxose和l ribose的非均相Pd–Bi / C催化剂†

  摘要：

  合成稀有糖的关键一步， 左旋糖 和 L-核糖，从相应的D-糖被氧化成内酯。人们发现，多相催化剂Pd-Bi / C可以代替分子氧化剂如溴或重铬酸吡啶鎓重铬酸盐直接用于分子氧的直接氧化。优化了催化剂的组成，并以5：1的原子比的Pd：Bi获得了最佳结果。五步程序的总产量为L-核糖 和 左旋糖分别为47％和50％。从总产率，减少的步骤数和温和的反应条件的观点来看，合成方法是有利的。此外，可以容易地从反应混合物中分离出非均相氧化催化剂，并在不损失活性的情况下对其进行再利用。

  DOI：

  10.1039/c1ob06116j
• 作为产物：
  描述：

  L-lyxose 在 硫酸 、 对甲苯磺酸 、 copper(II) sulfate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 2,3-O-isopropylidene-D-ribose
  参考文献：
  名称：

  Adenosine Kinase Inhibitors. 3. Synthesis, SAR, and Antiinflammatory Activity of a Series of l-Lyxofuranosyl Nucleosides

  摘要：

  Chronic inflammatory diseases, such as arthritis and rheumatoid arthritis, remain major health problems worldwide. We previously demonstrated that adenosine kinase inhibitors (AKIs) exhibit antiinflammatory effects by inhibiting TNF-alpha production, neutrophil accumulation, and edema formation. Although adenosine receptor agonists produce similar effects, AKIs showed the antiinflammatory activity without the cardiovascular side effects that prevented the development of adenosine receptor specific agonists. However, previously described potent AKIs, such as 5-iodotubercidin, are nucleosides which have the potential to undergo in vivo 5'-O-phosphorylation and therefore produce cytotoxicity. In an effort to eliminate toxicities produced by phosphorylated nucleosides, L-lyxofuranosyl analogues of tubercidin were tested as potential AKIs since the opposite stereochemical. orientation of the CH2OH was expected to eliminate intracellular phosphorylation. Described herein are the discovery of a new series of AKIs based on alpha-L-lyxofuranosyl. nucleosides, their SAR, as well as the antiinflammatory activity of the lead compound GP790 (IC50 = 0.47 nM, 47% inhibition of paw swelling at 10 mg/kg in rat carrageenan paw edema model). In addition, a study showing that in the skin lesion model the antiinflammatory activity is reversed by an A2 selective adenosine receptor antagonist 3,7-dimethyl-1-propylxanthine (DMPX) is also described.

  DOI：

  10.1021/jm030230z

文献信息

• Inhibitors of E1 activating enzymes
  申请人：Langston P. Steven

  公开号：US20070191293A1

  公开（公告）日：2007-08-16

  This invention relates to compounds that inhibit E 1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

  该发明涉及抑制E1激活酶的化合物，包括这些化合物的药物组合物，以及使用这些化合物的方法。这些化合物可用于治疗疾病，特别是细胞增殖性疾病，包括癌症、炎症和神经退行性疾病；以及与感染和消瘦相关的炎症。
• Lyxofuranosyl analogues of adenosine
  申请人：Gensia, Inc.

  公开号：US05506347A1

  公开（公告）日：1996-04-09

  Novel lyxose derivatives which selectively inhibit adenosine kinase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine.

  提供了一种新颖的利用甘露糖衍生物选择性抑制腺苷激酶的方法以及制备这些化合物的方法。这些化合物在治疗某些在体内可以通过增加局部腺苷浓度改善的疾病条件中是有用的。
• Enantiospecific synthesis of the hexahydrofuran unit of erythroskyrine, a pentaenoyltetramic acid metabolite
  作者：Raymond C. F. Jones、Mark Tankard

  DOI：10.1039/c39900000765

  日期：——

  A hexahydrofuro[3,2-b]furan unit suitably functionalised for incorporation into the synthesis of erythroskyrine has been prepared in homochiral form from diacetone-D-glucose.

  由双丙酮-D-葡萄糖以手性形式制备了被适当官能化以结合到赤藓基天青合成中的六氢呋喃[3，2- b ]呋喃单元。
• Synthesis and biological evaluation of new cross-conjugated dienone marine prostanoid analoguesElectronic supplementary information (ESI) available: 1H NMR, COSY and NOESY spectra. See http://www.rsc.org/suppdata/ob/b4/b404016c/
  作者：Cyrille Kuhn、Emmanuel Roulland、Jean-Claude Madelmont、Claude Monneret、Jean-Claude Florent

  DOI：10.1039/b404016c

  日期：——

  synthesis of a series of brominated cross-conjugated dienones, marine prostanoid analogues, was considered using two cyclopentannelation processes, from enamine (by a domino 3-aza Claisen/Mannich reaction) and from dioxolane ester alkylation followed by intramolecular Wittig reaction. All the compounds synthesized featured the same cross-conjugated dienone system, with a vicinal syn or anti diol on the omega-chain

  考虑使用两种环戊烯化方法，从烯胺（通过多米诺3-氮杂克莱森/曼尼希反应）和二氧戊环酯烷基化，再通过分子内维蒂希反应，合成一系列溴化的交叉共轭二烯酮，海洋类前列腺素类似物。合成的所有化合物均具有相同的交叉共轭二烯酮体系，在ω-链上具有邻位的顺式或反式二醇。天然前列腺素的ω-侧链被1-羟苯基-丁基部分取代，得到具有良好细胞毒性的新前列腺素（32-34）。在第二系列产品中，研究了带有简单苯基酯的较短α-侧链的可能性。结果表明细胞毒性显着增加（39、40、43、44）。最后，在第三个系列中 ω-1-羟苯基-丁基被1-羟甲基氧基苄基链取代。这些较简单的化合物（45、46、47、48、60）仍具有很高的细胞毒性，在60 nM的中等范围内，接近天然潘格列汀的价值。
• INHIBITORS OF E1 ACTIVATING ENZYMES
  申请人：Langston Steven P.

  公开号：US20120258927A1

  公开（公告）日：2012-10-11

  This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.

  本发明涉及抑制E1激活酶的化合物，包括该化合物的制药组合物和使用该化合物的方法。该化合物可用于治疗疾病，特别是细胞增殖性疾病，包括癌症、炎症和神经退行性疾病；以及与感染和消瘦相关的炎症。